비타민B2 (리보플라빈)

Vitamin B2 (riboflavin) and a mixture of vitamin B2 and C affects MMC efficiency in aerated media under irradiation.

1. Anticancer Res. 2004 Nov-Dec;24(6):4031-4. Vitamin B2 (riboflavin) and a mixture of vitamin B2 and C affects MMC efficiency in aerated media under irradiation. Fuga L(1), Kragl M, Getoff N. Author information: (1)Ludwig Boltzmann Institute for Radiation Chemistry and Radiation Biology, A-109

Potentiation by amino acid of the therapeutic effect of highly purified vitamin B2 in mice with lipopolysaccharide-induced shock.

2. Eur J Pharmacol. 2004 Jun 16;493(1-3):177-82. doi: 10.1016/j.ejphar.2004.04.019. Potentiation by amino acid of the therapeutic effect of highly purified vitamin B2 in mice with lipopolysaccharide-induced shock. Toyosawa T(1), Suzuki M, Kodama K, Araki S. Author information: (1)Tsukuba Researc

Is thallium-induced nephrotoxicity in rats connected with riboflavin and/or GSH?--reconsideration of hypotheses on the mechanism of thallium toxicity.

3. J Appl Toxicol. 1999 Jan-Feb;19(1):61-6. doi: 10.1002/(sici)1099-1263(199901/02)19:1<61::aid-jat539>3.0.co;2-s. Is thallium-induced nephrotoxicity in rats connected with riboflavin and/or GSH?--reconsideration of hypotheses on the mechanism of thallium toxicity. Appenroth D(1), Winnefeld K.

Potentiation of sodium chromate(VI)-induced chromosomal aberrations and mutation by vitamin B2 in Chinese hamster V79 cells.

4. Mutat Res. 1992 Nov;283(3):211-4. doi: 10.1016/0165-7992(92)90109-u. Potentiation of sodium chromate(VI)-induced chromosomal aberrations and mutation by vitamin B2 in Chinese hamster V79 cells. Sugiyama M(1), Tsuzuki K, Lin X, Costa M. Author information: (1)Department of Medical Biochemistry

Assessment of vitamin A, vitamin B(2), vitamin B(12), vitamin K, folate, and choline status following 4 months of multinutrient supplementation in healthy vegans: a randomised, double-blind, placebo-controlled trial.

1. Eur J Nutr. 2025 Dec 19;65(1):9. doi: 10.1007/s00394-025-03814-7. Assessment of vitamin A, vitamin B(2), vitamin B(12), vitamin K, folate, and choline status following 4 months of multinutrient supplementation in healthy vegans: a randomised, double-blind, placebo-controlled trial. Zerback T(1), Koeder C(2)(3), Weder S(1), Sputtek A(4), Eckert GP(5), Keller M(1). Author information: (1)Research Institute for Plant-Based Nutrition, 35444, Biebertal, Germany. (2)Institute for Prevention and Cancer Epidemiology (IPE), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79110, Freiburg im Breisgau, Germany. christiankoeder@gmail.com. (3)Research Institute for Plant-Based Nutrition, 35444, Biebertal, Germany. christiankoeder@gmail.com. (4)MVZ Medical Laboratory Bremen GmbH, 28359, Bremen, Germany. (5)Institute of Nutritional Sciences, Justus-Liebig University, 35392, Giessen, Germany. PURPOSE: The aim of the MultiVeg study, a double-blind, randomised controlled trial (RCT), was to investigate the nutritional status of healthy vegans following 4 months of multinutrient supplementation. METHODS: A double-blind, RCT was conducted with 72 vegan adults (19-57 years) in Germany. Data on anthropometric parameters, dietary nutrient intake, and nutritional status were collected. The nutritional status of the participants was assessed at baseline and after 4 months. The results were compared between groups using ANCOVA. The results for vitamins and choline are presented here. RESULTS: After adjustment for baseline values, age, sex, and multiple testing, no significant between-group differences in biomarker concentration changes from baseline to 4 months were observed for vitamin A, retinol-binding protein, transthyretin, beta-carotene, methylmalonic acid, homocysteine, choline, total osteocalcin, carboxylated and undercarboxylated osteocalcin, and folate. In contrast, significant between-group differences in changes were observed for flavin adenine dinucleotide (FAD), serum vitamin B12, holotranscobalamin, and the combined vitamin B12 status indicator (cB12) after adjustment. CONCLUSION: A multinutrient supplement containing 82 µg of vitamin B12 per day significantly positively affected vitamin B12 blood biomarkers in healthy vegans. REGISTRATION: This study was registered in the German Clinical Trials Register (DRKS00028151). © 2025. The Author(s). DOI: 10.1007/s00394-025-03814-7 PMCID: PMC12717231 PMID: 41417236 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Conflict of interest: T.Z., S.W., C.K., A.S., and G.P.E. declare no conflict of interest. M.K. is the managing director of the Research Institute of Plant-Based Nutrition (IFPE) which received funding from Watson Nutrition for conducting the study. Ethical approval: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethics committee of the Faculty of Medicine of the University of Giessen (57/22). Consent to participate: Written consent was obtained from all subjects involved in the study.

Riboflavin supplements for blood pressure lowering in adults.

2. Cochrane Database Syst Rev. 2025 Oct 22;10(10):CD015464. doi: 10.1002/14651858.CD015464.pub2. Riboflavin supplements for blood pressure lowering in adults. Bradbury KE(1), Coffey S(2), Earle N(3), Ni Mhurchu C(1), Jull AB(4). Author information: (1)School of Population Health, University of Auckland, Auckland, New Zealand. (2)Department of Medicine, University of Otago, Dunedin, New Zealand. (3)Department of Medicine, University of Auckland, Auckland, New Zealand. (4)School of Nursing, University of Auckland, Auckland, New Zealand. Update of doi: 10.1002/14651858.CD015464. RATIONALE: Higher blood pressure is strongly related to an increased risk of cardiovascular disease. There has been interest in riboflavin (vitamin B2) as a potential intervention to lower blood pressure, particularly for those with a common genetic polymorphism in the methylene tetrahydrofolate reductase enzyme (MTHFR). OBJECTIVES: To assess the benefits and harms of riboflavin supplements compared to placebo or no additional treatment for lowering systolic and diastolic blood pressure. SEARCH METHODS: We searched the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid Embase, Clarivate Web of Science, Clarivate Food Science & Technology Abstracts and two clinical trials registries. There were no restrictions on language, publication year, or publication status. The latest search date was 24 October 2024. We also handsearched the reference lists of included studies. ELIGIBILITY CRITERIA: We included randomised controlled trials (RCTs) conducted in adults that evaluated oral riboflavin supplements compared with an inactive control (e.g. placebo or no additional treatment) and measured at least one of the critical outcomes. We did not include trials that evaluated multivitamins containing riboflavin. Participants in both the intervention and control groups were able to receive standard medical therapy for hypertension prior to and during the trial. OUTCOMES: The critical outcomes were systolic blood pressure and diastolic blood pressure. The important outcomes were antihypertensive medication, adverse events and biomarkers of riboflavin status. RISK OF BIAS: We used the Cochrane RoB 2 tool to assess the risk of bias in included studies for the following outcomes: systolic blood pressure, diastolic blood pressure, antihypertensive medication and adverse events. SYNTHESIS METHODS: We used standard Cochrane methods. For the critical outcomes, which were continuous, we calculated mean differences (MD) and 95% confidence intervals (CIs). We used a fixed-effect meta-analysis to pool data for each outcome where possible. We conducted subgroup analyses, including by MTHFR C677T genotype. INCLUDED STUDIES: We included four RCTs, which contributed 374 total participants for quantitative synthesis, although the number of participants included for each outcome varied. Most included studies for most outcomes had an overall high risk of bias. SYNTHESIS OF RESULTS: The evidence is very uncertain about the effect of riboflavin on systolic blood pressure (MD -1.94 mmHg, 95% CI -5.74 to 1.86 mmHg; P = 0.32; 3 studies, 320 participants; very low-certainty evidence) and diastolic blood pressure (MD -3.03 mmHg, 95% CI -5.97 to -0.09 mmHg; P = 0.04; 2 studies, 271 participants; very low-certainty evidence). No RCTs reported data on changes in dose or number of antihypertensive medications. One RCT (54 participants) reported data on adverse events by intervention group; there were two adverse events in the riboflavin group and one in the control group. Low-certainty evidence suggests that riboflavin may result in little to no difference in adverse events. AUTHORS' CONCLUSIONS: The evidence for the effect of oral riboflavin supplements on systolic and diastolic blood pressure is very uncertain. The evidence comes from four RCTs, three of which had an overall high risk of bias. Large, well-conducted trials are needed for high-certainty evidence of the effect of riboflavin for blood pressure lowering. FUNDING: KEB was supported by a Sir Charles Hercus Health Research Fellowship from the Health Research Council (Grant number: 19/110) and a Senior Heart Foundation fellowship from the Heart Foundation of New Zealand, supported in part by the GR Winn Trust (Grant number: 3728679). REGISTRATION: Protocol (2023): DOI: 10.1002/14651858.CD015464. Copyright © 2025 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. DOI: 10.1002/14651858.CD015464.pub2 PMCID: PMC12541901 PMID: 41123035 [Indexed for MEDLINE] Conflict of interest statement: KEB: nothing to declare.
SC: nothing to declare.
NE: nothing to declare.
CNM: nothing to declare.
AJ: BMC Trials ‐ Other Professional Activities – Other; Health Research Council of New Zealand ‐ Grant / Contract and Other Professional Activities ‐ Data And Safety Monitoring; International Journal of Nursing Studies ‐ Employment; National Institute for Health Innovation ‐ Other Professional Activities ‐ Data And Safety Monitoring; National Institute for Health Research ‐ Other Professional Activities ‐ Data And Safety Monitoring; Smith and Nephew ‐ Travel; and University of Auckland ‐ Other Professional Activities ‐ Data And Safety Monitoring.

Antioxidant Treatment and the Chance to Conceive in Men Seeking Fertility Care: The SUMMER Randomized Clinical Trial.

3. JAMA Netw Open. 2025 Sep 2;8(9):e2532405. doi: 10.1001/jamanetworkopen.2025.32405. Antioxidant Treatment and the Chance to Conceive in Men Seeking Fertility Care: The SUMMER Randomized Clinical Trial. de Ligny WR(1)(2), de Bruin JP(2), Smits RM(1), Goovaerts IGF(3), Peeters K(3), Nap AW(1), Boxmeer JC(4), Donker RB(5), Schoonenberg M(6), Koks CAM(7), van Rumste MME(8), Visser J(9), Gielen SCJP(10), Boomsma CM(11), Smeenk JMJ(12), van Oppenraaij RHF(13), Cox T(14), Janse F(15), Muller LT(16), Brink-van der Vlugt JJ(17), Braat DDM(1), Fleischer K(6). Author information: (1)Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands. (2)Department of Obstetrics and Gynecology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands. (3)Center of Reproductive Medicine, Antwerp University Hospital, Edegem, Belgium. (4)Center of Reproductive Medicine, Voorburg Reinier de Graaf, Voorburg, the Netherlands. (5)Department of Obstetrics and Gynecology, Slingeland Hospital, Doetinchem, the Netherlands. (6)Nij Geertgen Center for Reproductive Medicine, Elsendorp, the Netherlands. (7)Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, the Netherlands. (8)Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, the Netherlands. (9)Department of Obstetrics and Gynecology, Amphia Hospital, Breda, the Netherlands. (10)Department of Obstetrics and Gynecology, Franciscus Hospital, Rotterdam, the Netherlands. (11)Department of Obstetrics and Gynecology, Bravis Hospital, Roosendaal, the Netherlands. (12)Department of Obstetrics and Gynecology, Elisabeth TweeSteden Hospital, Tilburg, the Netherlands. (13)Department of Obstetrics and Gynecology, Maasstad Hospital, Rotterdam, the Netherlands. (14)Department of Obstetrics and Gynecology, Medisch Centrum Kinderwens, Leiderdorp, the Netherlands. (15)Department of Obstetrics and Gynecology, Rjinstate Hospital, Arnhem, the Netherlands. (16)Department of Obstetrics and Gynecology, Bernhoven Hospital, Uden, the Netherlands. (17)Nij Barrahûs Center for Reproductive Medicine, Wolvega, the Netherlands. IMPORTANCE: Treatments for men seeking fertility care are limited. Antioxidant supplements have been widely studied as a new treatment option, but these studies have had conflicting results. OBJECTIVE: To assess whether treatment of men seeking fertility care with an antioxidant supplement can improve semen quality and pregnancy rates compared with a placebo. DESIGN, SETTING, AND PARTICIPANTS: The SUMMER trial was a multicenter, double-blind, placebo-controlled randomized clinical trial conducted in 21 hospitals and private fertility clinics in the Netherlands. Male patients in these centers were enrolled between May 2018 and February 2024, and follow-up of the primary outcome was completed in December 2024. Eligible participants were men aged 18 to 50 years with female partners aged 18 to 43 years, who sought fertility care and were advised to undergo expectant management, treatment with intrauterine insemination, in vitro fertilization (IVF), or intracytoplasmic sperm injection (ICSI). Couples treated with ovulation induction only or IVF for bilateral tubal pathology were excluded. The men were randomly assigned to receive an antioxidant supplement or a placebo. Intention-to-treat analysis was performed for all outcomes. INTERVENTIONS: The antioxidant supplement (Impryl) was a tablet to be taken daily for 6 months. It contained betaine (200 mg), L-cystine (200 mg), niacin (16 mg), zinc (10 mg), vitamin B6 (1.4 mg), vitamin B2 (1.4 mg), folic acid (400 µg), and vitamin B12 (2.5 µg). The placebo tablet and its packaging were identical to those of the antioxidant supplement. All participating couples received standard infertility care. MAIN OUTCOMES AND MEASURES: The primary outcome was ongoing pregnancy conceived within 6 months after randomization. Secondary outcomes included semen parameters, sperm DNA fragmentation, fertilization and embryo utilization rates after IVF or ICSI, biochemical and clinical pregnancy rates, first-trimester pregnancy loss, ectopic pregnancy rate, cumulative number of pregnancies, time to pregnancy, and adverse events. RESULTS: A total of 1171 men (median [IQR] age, 34 [31-38] years; female partners' median [IQR] age, 32 [30-35] years) were included in the data analysis, of whom 591 were in the antioxidant supplement group and 580 were in the placebo group. Ongoing pregnancy rate within 6 months was not significantly different between the 2 groups (193 of 571 [33.8%] vs 208 of 555 [37.5%]; adjusted odds ratio [AOR], 0.85 [95% CI, 0.66-1.09]; P = .20). Within the window of optimal treatment effect between 4 and 6 months (considering a spermatogenesis cycle of 72 days), ongoing pregnancy rate was significantly lower in the antioxidant supplement group compared with the placebo group (69 of 446 [15.5%] vs 95 of 442 [21.5%]; AOR, 0.66 [95% CI, 0.47-0.94]; P = .02). There were no significant between-group differences for the secondary outcomes. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that ongoing pregnancy rates did not improve with the antioxidant supplement compared with a placebo. Therefore, the investigators do not support its use in men seeking fertility care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03337360. DOI: 10.1001/jamanetworkopen.2025.32405 PMCID: PMC12464787 PMID: 40996763 [Indexed for MEDLINE] Conflict of interest statement: Conflict of Interest Disclosures: Dr de Ligny reported receiving an unrestricted research grant and study medications from Goodlife Pharma BV during the conduct of the study and educational support from Ferring outside the submitted work. Dr de Bruin reported receiving an unrestricted research grant from Goodlife Pharma BV during the conduct of the study. Dr Smits reported receiving an unrestricted research grant from Goodlife Pharma BV during the conduct of the study. Dr van Rumste reported receiving personal fees from Ferring BV and Merck Group outside the submitted work. Dr Smeenk reported receiving grants from Merck BV, Ferring BV, and Goodlife Pharma BV outside the submitted work. Dr Fleischer reported receiving an unrestricted research grant from Goodlife Pharma BV during the conduct of the study. No other disclosures were reported.

Impact of Vitamin B1 and Vitamin B2 Supplementation on Anxiety, Stress, and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial.

4. Nutrients. 2025 May 27;17(11):1821. doi: 10.3390/nu17111821. Impact of Vitamin B1 and Vitamin B2 Supplementation on Anxiety, Stress, and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial. Tao Y(1), Wu M(1), Su B(1), Lin H(1), Li Q(1), Zhong T(1), Xiao Y(1), Yu X(1). Author information: (1)Faculty of Medicine, Macau University of Science and Technology, Avenida Wai Long Taipa, Macau. Background: Anxiety, stress, and sleep disturbances significantly affect overall health. Research suggests that vitamins B1 and B2 may play a role in mood regulation and neuroprotection. This study aimed to investigate the effects of vitamin B1 and B2 supplementation in alleviating anxiety and stress and improving sleep quality. Methods: This study was a parallel randomized, double-blind, placebo-controlled clinical trial. Participants (n = 43) were randomized to receive one of the following two interventions: 100 mg of vitamin B1 and 100 mg of vitamin B2 or placebo. Intervention outcomes were assessed at baseline and week four, including SAS (Self-Rating Anxiety Scale), PSS (Perceived Stress Scale), PSQI (Sleep Quality Index), ESS (Sleepiness Scale), and measurement of urinary vitamin B1 and B2 levels. Results: After four weeks, urinary vitamin B1 levels increased from 158 ± 108.9 ng to 1333.1 ± 1204.5 ng (p < 0.01), and urinary vitamin B2 levels increased from 308.0 ± 198.3 ng to 6123.2 ± 4847.2 ng in the supplement group (p < 0.01). The PSS scores decreased significantly in the supplement group from 21.5 ± 4.1 to 15.5 ± 4.5 (p < 0.05), while the placebo group showed a change from 20.3 ± 4.3 to 19.8 ± 5.5. Vitamins B1 and B2 did not have a significant effect on anxiety improvement (p > 0.05). The PSQI scores decreased in the supplement group from 8.0 ± 3.12 to 6.3 ± 2.0 (p < 0.05), while the placebo group worsened from 5.7 ± 2.7 to 7.4 ± 2.9. Meanwhile, the ESS scores in the supplement group decreased from 13.0 ± 3.4 to 9.1 ± 3.9 (p < 0.05), demonstrating a significant improvement compared to the placebo group. Conclusions: The clinical trial findings demonstrated that while vitamin B1 and B2 supplements helped reduce stress, enhance sleep, and reduce sleepiness, they had no discernible impact on reducing anxiety. Future studies should focus on the long-term effects of vitamin B1 and B2 supplements, exploring the combined effects of combined vitamin B1 and B2 medications for the treatment of stress and sleep disorders. DOI: 10.3390/nu17111821 PMCID: PMC12157762 PMID: 40507089 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.

A randomized multi-arm open labelled comparative clinical trial report of Pankajakasthuri DiabetEaze powder, a novel polyherbal formulation on the nutritional management and glycemic control in type 2 diabetic and prediabetic patients.

5. Heliyon. 2025 Feb 13;11(4):e42631. doi: 10.1016/j.heliyon.2025.e42631. eCollection 2025 Feb 28. A randomized multi-arm open labelled comparative clinical trial report of Pankajakasthuri DiabetEaze powder, a novel polyherbal formulation on the nutritional management and glycemic control in type 2 diabetic and prediabetic patients. Sasidharan S(1)(2), Nair A K(3), R L(3), Nair AV(4), Sa S(5), Joseph SG(6), Chand Cp A(3), Satheesan S(7), Pratap A(3), Kumar S N(2), Paul J(8), Nair V V(9), R V(6), Nair J H(4). Author information: (1)HCEMM-SU Cardiovascular Comorbidities Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1089, Budapest, Hungary. (2)Department of R&D, Pankajakasthuri Herbal Research Foundation, Pankajakasthuri Ayurveda Medical College Campus, Trivandrum, India. (3)Department of Kayachikitsa, Pankajakasthuri Ayurveda Medical College & PG Centre, Killy, Kattakada, Thiruvananthapuram, Kerala, India. (4)Pankajakasthuri Herbals India Pvt. Ltd., Poovachal, Trivandrum, India. (5)Department of Rasashastra & Bhaishajya Kalpana, Pankajakasthuri Ayurveda Medical College & P.G. Centre, Killy, Kattakada, Thiruvananthapuram, Kerala, India. (6)Department of Dravyagunavijnanam, Pankajakasthuri Ayurveda Medical College & P.G. Centre, Killy, Kattakada, Thiruvananthapuram, Kerala, India. (7)Department of Shalyatantra, Pankajakasthuri Ayurveda Medical College & PG Centre, Killy, Kattakada, Thiruvananthapuram, Kerala, India. (8)Department of Statistics, Vimala College (Autonomous), Thrissur, Kerala, 680009, India. (9)Neyyar Medicity, Killy, Kattakada, Thiruvananthapuram, Kerala, India. BACKGROUND AND AIMS: Recently Diabetes Mellitus (DM) has been associated with heightened susceptibility to malnutrition, suggesting that augmenting nutritional intake stands out as a potent therapeutic strategy for addressing malnutrition in individuals with DM. The aim of this clinical investigation was to evaluate the effect of DiabetEaze powder, a polyherbal nutritional formulation developed by us for nutritional management and glycaemic control, on patients with diabetic and prediabetic conditions. METHODS: A total of 143 type II diabetic (T2D) patients who were managing their diabetic condition through modern medicine, AYUSH medicine, lifestyle modification and 68 pre-diabetic patients, aged between 40 and 65 years, were randomly assigned into six groups: control, modern, AYUSH, lifestyle, prediabetic control and prediabetic trial. The treatment groups were administered 5 g of DiabetEaze powder two times a day after food for 6 months. Microminerals, vitamins, glycaemic parameters, Quality of Life (QoL), hematology, lipid profiles, Renal Function Test (RFT) and Liver Function Test (LFL) parameters, and electrolytes were evaluated at Day 0, Day 90, and Day 180. RESULTS: Out of 211 enrolled patients, 189 individuals successfully completed the entire 180-day duration of the study, indicating a retention rate of approximately 89.6 %. In our study, we observed a statistically significant elevation in the levels of vitamin D, B2, and B6 across all treatment groups. Besides, the treatment groups displayed a notable increase in zinc and manganese levels compared to the other minerals tested. Notably, the treatment groups demonstrated distinct mineral and vitamin profiles. In terms of metabolic markers, significant reductions in Fasting Blood Sugar (FBS)/Post Prandial Blood Sugar (PPBS) were observed across the modern, AYUSH, and lifestyle groups, while the modern group also showed a marked decrease in glycated haemoglobin (HbA1c) levels. Furthermore, overall QoL among the tested groups was also statistically significant. The consistent maintenance of normal LFT and RFT parameters and electrolyte levels across trial groups throughout the study duration indicates that the supplement does not induce liver toxicity or negatively impact hepatic function. CONCLUSION: In conclusion, the nutrients present in the DiabetEaze powder contribute to the effective management of nutritional status in diabetic people and thus effectively reduce sugar spikes by regulating PPBS and HbA1c levels, which is a critical aspect of its role in diabetes management. These properties benefit in managing diabetes-related outcomes and overall quality of life. CLINICAL TRIAL REGISTRY OF INDIA UNDER REGISTRATION NO: CTRI/2021/04/032956 on 20/04/2021. © 2025 The Authors. DOI: 10.1016/j.heliyon.2025.e42631 PMCID: PMC11903805 PMID: 40083990 Conflict of interest statement: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Dr. Shan Sasidharan reports financial support was provided by Department of Pharmacology and Pharmacotherapy, Semmelweis University & Pankajakasthuri Ayurveda Medical College & PG Centre, Killy, Kattakada, Thiruvananthapuram, Kerala, India. Dr. Shan Sasidharan reports a relationship with Department of Pharmacology and Pharmacotherapy, Semmelweis University & Pankajakasthuri Ayurveda Medical College & PG Centre, Killy, Kattakada, Thiruvananthapuram, Kerala, India that includes: employment. Dr. Shan Sasidharan has patent nil pending to nil. nil If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Evaluating the Efficacy of Probiotics on Disease Progression, Quality of Life, and Nutritional Status Among Patients with Crohn's Disease: A Multicenter, Randomized, Single-Blinded Controlled Trial.

6. Nutrients. 2025 Feb 17;17(4):708. doi: 10.3390/nu17040708. Evaluating the Efficacy of Probiotics on Disease Progression, Quality of Life, and Nutritional Status Among Patients with Crohn's Disease: A Multicenter, Randomized, Single-Blinded Controlled Trial. Hoteit M(1)(2)(3), Hellani M(4)(5), Karaja M(4)(5), Zayour N(2)(3), Sadek Z(2)(6)(7), Hotayt B(8), Hallal M(4)(5). Author information: (1)Food Sciences Unit, National Council for Scientific Research of Lebanon (CNRS-L), Beirut P.O. Box 11-8281, Lebanon. (2)PHENOL Research Program, Faculty of Public Health, Section 1, Lebanese University, Beirut P.O. Box 6573, Lebanon. (3)Organized Research Unit, Zahraa University Medical Center (ZHUMC), Beirut P.O. Box 90-361, Lebanon. (4)Gastroenterology Department, Faculty of Medical Science, Lebanese University, Beirut P.O. Box 14-6573, Lebanon. (5)Gastroenterology and Hepatology Department, Zahraa University Medical Center (ZHUMC), Beirut P.O. Box 90-361, Lebanon. (6)Physiotherapy Department, Faculty of Public Health, Islamic University of Lebanon, Khaldeh P.O. Box 30014, Lebanon. (7)Physiotherapy Department, Faculty of Public Health, Lebanese University, Beirut P.O. Box 6573-1, Lebanon. (8)Badaro Endoscopic Center, Moarbes Hospital, Beirut P.O. Box 50-223, Lebanon. BACKGROUND: There is growing interest in the role of gut microbiota in the pathophysiology of inflammatory bowel diseases (IBDs), including Crohn's disease (CD). Probiotics have been proposed as a potential adjunct therapy for these conditions by altering the intestinal environment, although studies on their effectiveness have yielded mixed results. AIM: This study aims to evaluate the short-term (2 months) effects of a dietary supplement containing Lactobacilli, Bifidobacteria, and Lactococcus bacillus on disease progression, remission, quality of life, and nutritional intake in Lebanese patients with CD. METHOD: A multicenter, randomized, single-blind controlled trial was conducted in 2 medical centers in Beirut from 1 April 2024 to 1 August 2024. Recruitment, prescreening, screening, enrollment, and protocol implementation were carried out at both centers. Data were collected from 21 patients with CD, who were randomly assigned to the control group (n = 10) and the intervention group (n = 11). At baseline and after two months, participants underwent clinical assessments, WHOQOL-BREF evaluation, and 24 h dietary recalls. Follow-up visits included surveys on disease progression, quality of life, adherence, and adverse events, along with repeat body composition and anthropometric measurements. RESULTS: Probiotic supplementation over two months did not significantly alter symptoms, flares, or hospitalizations outcomes between the control and intervention groups. However, the intervention group experienced notable increases in body weight (p = 0.01), BMI (p = 0.01), body fat mass (p = 0.04), and arm muscle circumference (p = 0.01). Nutrient intake patterns differed, with the intervention group showing increased consumption of calcium, riboflavin, and folate compared to controls (p = 0.01, p = 0.04, p = 0.013, respectively). Probiotic supplementation led to significant within-group increases in dietary fiber (p = 0.01), total sugar (p = 0.02), and caffeine (p = 0.01) among the intervention participants. Adverse effects in the intervention group were mild, including nausea (18.2%) and abdominal discomfort (9.1%). QOL improved significantly in the intervention group, particularly in physical (p = 0.03), psychological (p = 0.04), and environmental domains (p = 0.003), while the control group exhibited improvements only in psychological health. CONCLUSIONS: Overall, the findings suggest that probiotics can enhance body composition, nutrient intake, and certain aspects of QOL among CD patients, despite minimal impact on disease symptoms or dietary patterns. DOI: 10.3390/nu17040708 PMCID: PMC11858769 PMID: 40005035 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.

Effects of selected dietary supplements on migraine prophylaxis: A systematic review and dose-response meta-analysis of randomized controlled trials.

7. Neurol Sci. 2025 Feb;46(2):651-670. doi: 10.1007/s10072-024-07794-0. Epub 2024 Oct 15. Effects of selected dietary supplements on migraine prophylaxis: A systematic review and dose-response meta-analysis of randomized controlled trials. Talandashti MK(1), Shahinfar H(2)(3), Delgarm P(1), Jazayeri S(4). Author information: (1)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. (2)Department of Nutrition, School of Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran. (3)Nutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. (4)Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. jazayeri.sh@iums.ac.ir. BACKGROUND: The existing evidence on the effect of dietary supplements for preventing migraines has generated conflicting results. METHODS: We assessed alterations in migraine clinical features corresponding to the intake of dietary supplements. Our main outcomes included the frequency (number of attacks), duration (in hours), the severity (intensity) and the monthly migraine days. Using a dose-response meta-analysis, we estimated the dose-dependent impact. The certainty of evidence was evaluated using the GRADE tool. RESULTS: Finally, twenty-two trials were included in the systematic review and meta-analysis. Magnesium supplementation reduced migraine attacks (mean difference (MD) = -2.51), severity (MD = -0.88), and the monthly migraine days (MD = -1.66) compared with the control group. CoQ10 decreased the frequency (MD = -1.73), severity (MD = -1.35), and duration of migraine (MD = -1.72). Riboflavin decreased attack frequency (MD = -1.34). Alpha-lipoic acid decreased attack frequency (MD = -1.24) and severity (MD = -0.38). Probiotics decreased the frequency (MD = -1.16), severity (MD = -1.07) and the monthly migraine days (MD = -3.02). Vitamin D reduced migraine frequency (MD = -1.69) and the monthly migraine days (MD = -2.41). In adults, compared with placebo, these supplements did not significantly affect other outcomes, and omega-3 supplementation did not yield a statistically significant reduction in any of these outcomes. CONCLUSION: The use of certain dietary supplements has resulted in a significant decrease in migraine prophylaxis. Further clinical trials of high quality appear to be beneficial. © 2024. Fondazione Società Italiana di Neurologia. DOI: 10.1007/s10072-024-07794-0 PMID: 39404918 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethical approval: 1) This material is the authors’ own original work, which has not been previously published elsewhere. 2) The paper is not currently being considered for publication elsewhere. 3) The paper reflects the authors’ own research and analysis in a truthful and complete manner. 4) The authors have no conflict of interest. Conflict of interest: The authors declared no conflicts of interest.

Enhancing gut microbiota and microbial function with inulin supplementation in children with obesity.

8. Int J Obes (Lond). 2024 Dec;48(12):1696-1704. doi: 10.1038/s41366-024-01590-8. Epub 2024 Jul 20. Enhancing gut microbiota and microbial function with inulin supplementation in children with obesity. Visuthranukul C(1), Sriswasdi S(2)(3), Tepaamorndech S(4), Chamni S(5), Leelahavanichkul A(4)(6), Joyjinda Y(7)(8), Aksornkitti V(3)(9), Chomtho S(10). Author information: (1)Center of Excellence in Pediatric Nutrition, Division of Nutrition, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. chonnikant.v@chula.ac.th. (2)Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (3)Center of Excellence in Computational Molecular Biology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (4)Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (5)Center of Excellent in Natural Products and Nanoparticles (NP2), Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand. (6)Center of Excellence in Inflammation and Immunology Research Unit (CETRII), Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (7)WHO-CC for Research and Training on Viral Zoonoses, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (8)Thai Red Cross Emerging Infection Diseases-Health Science Center, Bangkok, 10330, Thailand. (9)Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. (10)Center of Excellence in Pediatric Nutrition, Division of Nutrition, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. BACKGROUND AND OBJECTIVES: Gut dysbiosis that resulted from the alteration between host-microbe interaction might worsen obesity-induced systemic inflammation. Gut microbiota manipulation by supplementation of prebiotic inulin may reverse metabolic abnormalities and improve obesity. This study aimed to determine whether inulin supplementation improved intestinal microbiota and microbial functional pathways in children with obesity. METHODS: Children with obesity whose BMI above median + 2SDs were recruited to a randomized, double-blinded placebo-controlled study. The participants aged 7-15 years were assigned to inulin supplement extracted from Thai Jerusalem artichoke (intervention), maltodextrin (placebo), and dietary fiber advice groups. All participants received similar monthly conventional advice and follow-up for 6 months. Fecal samples were collected for gut microbiome analysis using 16S rRNA sequencing. Phylogenetic Investigation of Communities by Reconstruction of Unobserved States was performed to infer microbial functional pathways. RESULTS: One hundred and forty-three children with available taxonomic and functional pathway abundance profiles were evaluated. A significant increase in alpha-diversity was observed in the inulin group. Inulin supplementation substantially enhanced Bifidobacterium, Blautia, Megasphaera, and several butyrate-producing bacteria, including Agathobacter, Eubacterium coprostanoligenes, and Subdoligranulum, compared to the other groups. The inulin group showed a significant difference in functional pathways of proteasome and riboflavin metabolism. These changes correlated with clinical and metabolic outcomes exclusively in the inulin group. CONCLUSIONS: Inulin supplementation significantly promoted gut bacterial diversity and improved gut microbiota dysbiosis in children with obesity. The modulation of functional pathways by inulin suggests its potential to establish beneficial interactions between the gut microbiota and host physiology. Inulin supplementation could be a strategic treatment to restore the balance of intestinal microbiota and regulate their functions in childhood obesity. © 2024. The Author(s). DOI: 10.1038/s41366-024-01590-8 PMCID: PMC11584386 PMID: 39033197 [Indexed for MEDLINE] Conflict of interest statement: Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The research involving human subjects, human material, and human data was in accordance with the Declaration of Helsinki. The study was approved by the Institutional Review Board, Faculty of Medicine, Chulalongkorn University (IRB no. 240/60). Informed assent and consent were obtained from all participants and their parents prior to enrollment.

A Clinical Trial Shows Improvement in Skin Collagen, Hydration, Elasticity, Wrinkles, Scalp, and Hair Condition following 12-Week Oral Intake of a Supplement Containing Hydrolysed Collagen.

9. Dermatol Res Pract. 2024 Jul 10;2024:8752787. doi: 10.1155/2024/8752787. eCollection 2024. A Clinical Trial Shows Improvement in Skin Collagen, Hydration, Elasticity, Wrinkles, Scalp, and Hair Condition following 12-Week Oral Intake of a Supplement Containing Hydrolysed Collagen. Reilly DM(1), Kynaston L(1), Naseem S(1), Proudman E(1), Laceby D(1). Author information: (1)Absolute Collagen, 6 Bennetts Hill, Birmingham B2 5ST, UK. BACKGROUND: Hydrolysed collagen supplements are reported to fight the signs of aging and improve skin appearance, but more authoritative clinical evidence is needed to support efficacy. AIM: This randomised, double-blind, placebo-controlled study evaluated the efficacy of a supplement containing hydrolysed collagen and vitamin C (Absolute Collagen, AC) on biophysical parameters and visible signs of aging for skin, scalp, and hair, when taken daily or every 48 hours. METHODS: We measured dermal collagen using confocal microscopy and high-resolution ultrasound. Hydration, elasticity, wrinkles, and clinical trichoscopy were measured in parallel to expert visual grading. Efficacy measures were recorded at baseline, week 6, and week 12. RESULTS: Following 12 weeks daily use of the AC supplement, using confocal microscopy, we observed a significant 44.6% decrease in fragmentation vs. placebo (p < 0.01). We also measured a change in the ultrasound LEP (low echogenic pixel) ratio comparing upper and lower dermis (-9.24 vs. -7.83, respectively, p=0.05), suggesting collagen improvements occurred more in the upper dermal compartment. After 12 weeks vs. placebo, skin hydration was increased by 13.8% (p < 0.01), R2 elasticity index was increased by 22.7% (p<0.01), and Rz profilometry index was decreased by 19.6% (p < 0.01). Trichoscopy showed an average 11.0% improvement in scalp scaling and a 27.6% increase in the total number of hairs counted vs. placebo (p=n.s.). This was associated with a 31.9% increase in clinical grading score for hair healthy appearance (p < 0.01). CONCLUSION: The AC supplement has shown clinical benefits for skin, scalp, and hair, when used either daily or every 48 hours, over a 12-week period. Copyright © 2024 David M. Reilly et al. DOI: 10.1155/2024/8752787 PMCID: PMC11254459 PMID: 39021368 Conflict of interest statement: The authors declare that there are no conflicts of interest.

Higher Plasma Myo-Inositol in Pregnancy Associated with Reduced Postpartum Blood Loss: Secondary Analyses of the NiPPeR Trial.

10. Nutrients. 2024 Jun 27;16(13):2054. doi: 10.3390/nu16132054. Higher Plasma Myo-Inositol in Pregnancy Associated with Reduced Postpartum Blood Loss: Secondary Analyses of the NiPPeR Trial. Chang HF(1), Yong HEJ(2), Zhang H(2), Wong JT(2), Barton SJ(3), Titcombe P(3), Albert BB(4), El-Heis S(3)(5), Nield H(3), Ong J(1), Lavelle L(6), Ramos-Nieves JM(6), Godin JP(6), Silva-Zolezzi I(7), Cutfield WS(4), Godfrey KM(3)(5), Chan SY(1)(2)(8), The NiPPeR Study Group. Author information: (1)Department of Obstetrics and Gynaecology, National University Hospital, Singapore 119074, Singapore. (2)Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore 117609, Singapore. (3)MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton SO16 6YD, UK. (4)Liggins Institute and a Better Start-National Science Challenge, The University of Auckland, Auckland 1023, New Zealand. (5)NIHR Southampton Biomedical Research Centre, University of Southampton & University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK. (6)Nestlé Research Centre, 1000 Lausanne, Switzerland. (7)Research & Development, Nestlé Product Technology Center-Nutrition, 1800 Vevey, Switzerland. (8)Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore. We previously reported that a combined myo-inositol, probiotics, and enriched micronutrient supplement (intervention) taken preconception and in pregnancy reduced postpartum blood loss (PBL) and major postpartum hemorrhage compared with a standard micronutrient supplement (control), as secondary outcomes of the NiPPeR trial. This study aimed to identify the intervention components that may contribute to this effect. Associations of plasma concentrations of myo-inositol and vitamins B2, B6, B12, and D at preconception (before and after supplementation), early (~7-weeks), and late pregnancy (~28-weeks) with PBL were assessed by multiple linear regression, adjusting for site, ethnicity, preconception BMI, parity, and previous cesarean section. Amongst 583 women, a higher concentration of myo-inositol in early pregnancy was associated with a PBL reduction [βadj -1.26 (95%CI -2.23, -0.29) mL per µmol/L myo-inositol increase, p = 0.011]. Applying this co-efficient to the increase in mean 7-week-myo-inositol concentration of 23.4 µmol/L with the intervention equated to a PBL reduction of 29.5 mL (~8.4% of mean PBL of 350 mL among controls), accounting for 84.3% of the previously reported intervention effect of 35 mL. None of the examined vitamins were associated with PBL. Therefore, myo-inositol may be a key intervention component mediating the PBL reduction. Further work is required to determine the mechanisms involved. DOI: 10.3390/nu16132054 PMCID: PMC11242953 PMID: 38999805 [Indexed for MEDLINE] Conflict of interest statement: S.-Y.C., W.S.C., and K.M.G. are part of an academic consortium that report grants from Soci&eacute;t&eacute; Des Produits Nestl&eacute; S.A. during the conduct of the study and are co-inventors on patent filings by Nestl&eacute; S.A. relating to the NiPPeR intervention or its components. S.-Y.C. has received reimbursement and honoraria into her research funds from Nestl&eacute; Nutrition Institute and EGOI (Experts Group on Inositols) for speaking at conferences. K.M.G. has received reimbursement for speaking at conferences sponsored by companies selling nutritional products. L.L., J.M.R.-N., J.-P.G., and I.S.-Z. are employees of Soci&eacute;t&eacute; Des Produits Nestl&eacute; S.A. All other authors declare no competing interests.

The role of nutraceuticals in the management of temporomandibular disorders.

11. J Complement Integr Med. 2024 Jul 4;21(4):540-547. doi: 10.1515/jcim-2023-0394. eCollection 2024 Dec 1. The role of nutraceuticals in the management of temporomandibular disorders. Di Giacomo P(1), Forte G(2), Capogna I(1), Casagrande M(2), Di Paolo C(1). Author information: (1)Department of Oral and Maxillo-Facial Sciences, 209311 Sapienza University of Rome , Rome, Italy. (2)Department of Psychology, 209311 Sapienza University of Rome , Rome, Italy. OBJECTIVES: Temporomandibular disorders (TMDs) are usually treated with occlusal appliances and supportive treatments such as physical therapy and drugs. Supplements can be included among potential supportive therapies, with the aim of reducing the use of drugs. To evaluate the efficacy of nutraceuticals' short-term treatment in subjects with temporomandibular disorders. METHODS: The study started in January 2021 and ended in January 2022. Subjects with temporomandibular disorders and a verbal numeric scale >40 were recruited and randomly assigned to one of the following groups. If waiting to start a therapy, to the nutraceutical group or to the no treatment group, while if already undergoing splint therapy, to nutraceautical+splint group or to splint therapy group. Nutraceutical used was composed by Boswellia Serrata Casperome, Magnesium, Tryptophan and vitamins B2 and D with a posology of one tablet/day before sleep for 40 days. Presence of temporomandibular pain, headache, neck pain and sleep/emotional disorders were assessed at T0 and at T1, after 40 days. ANOVA was performed to compare treatments with nutraceuticals and their respective controls, as for the variables related to painful symptomatology. Chi-squared was conducted to assess differences in sleep/emotional disorders between groups. The statistical significance was p<0.05. RESULTS: The groups using nutraceuticals showed statistically significant improvements over controls for most of the variables analyzed. CONCLUSIONS: The use of nutraceutical seems to be a valuable support for TMD therapy in the short term either alone or combined with occlusal splint therapy. © 2024 the author(s), published by De Gruyter, Berlin/Boston. DOI: 10.1515/jcim-2023-0394 PMID: 38958698 [Indexed for MEDLINE]

Effects of Cucurbita Moschata squash (Butternut) seed paste in improving zinc and iron status in children attending Early Childhood Development centres in Limpopo province, South Africa.

12. PLoS One. 2024 Apr 18;19(4):e0300845. doi: 10.1371/journal.pone.0300845. eCollection 2024. Effects of Cucurbita Moschata squash (Butternut) seed paste in improving zinc and iron status in children attending Early Childhood Development centres in Limpopo province, South Africa. Motadi SA(1)(2), Mbhenyane XG(1), Zuma MK(1)(3), Freeland Graves JH(4). Author information: (1)Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. (2)Department of Nutrition, Faculty of Health Sciences, University of Venda, Thohoyandou, South Africa. (3)Smallholder Agricultural Development, Agricultural Research Council, Pretoria, South Africa. (4)Nutritional Sciences, University of Texas at Austin, Austin, Texas, United States of America. Cucurbita moschata (Butternut squash) seeds are a rich source of nutrition containing nutrients including iron, zinc, copper, calcium, potassium, and phosphorus. The aim of this study was to determine if Cucurbita Moschata squash seed paste improves zinc and iron status, anthropometric status, and dietary intake in preschool children. A pretest-posttest control group trial using cluster randomisation was conducted over 6 months. Four preschools were randomly assigned to receive 100 g of intervention or 100 g of a placebo as the control to enhance iron and zinc status. A total of 276 preschool children were recruited from eight government registered Early Childhood Development centres in Limpopo province, South Africa. The control group consumed Cucurbita moschata flesh twice-weekly, while the intervention group consumed Cucurbita moschata seed paste twice-weekly during a six-month period. Iron (serum iron, transferrin, transferrin saturation, ferritin) and zinc (serum zinc) status and anthropometric indices such as weight, height and mid upper arm circumference for children were evaluated at baseline and the endpoint. Iron and zinc-rich food consumption was measured using a 24-hour dietary recall and food record during the study, and dietary intake was estimated using a food frequency questionnaire which was conducted at the beginning and endpoint. The intervention group significantly improved in the mean serum iron 0.23 μg/dL (95% CI: 0.11;0.33); ferritin 0.21μg/dL (95% CI: 0.13;0.39), transferrin saturation 0.33% (0.23;0.74) and zinc 0.16 μmol/dl (95% CI: 0.13;0.25) at the end of the study. In addition, the intervention group exhibited greater mean weight for age of 0.13 z-score (95% CI: 0.28; 0.34) and weight for height of 0.04 z-score (95% CI: 0.12,0.05), as well as the consumption of iron (p < 0,001), zinc (p < 0,001), and vitamin C (p < 0.001). At the end of the trial, fiber (p < 0.001), riboflavin (p = 0.001), vitamin B6 (p < 0.001), and vitamin B12 (p < 0.001) were significantly higher in the control group. Thus, the inclusion of intervention in the diet of children in an impoverished area of South Africa improved the iron and zinc status of these children. This supplement could be a cost effective and sustainable approach to improve nutrient status in rural South Africa. Trial registration: Pan African Clinical Trial Registry (PACTR202308740458863). Copyright: © 2024 Motadi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. DOI: 10.1371/journal.pone.0300845 PMCID: PMC11025940 PMID: 38635826 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that they have no conflict of interest.

A nutritional supplement during preconception and pregnancy increases human milk vitamin D but not B-vitamin concentrations.

13. Clin Nutr. 2023 Dec;42(12):2443-2456. doi: 10.1016/j.clnu.2023.09.009. Epub 2023 Oct 5. A nutritional supplement during preconception and pregnancy increases human milk vitamin D but not B-vitamin concentrations. Han SM(1), Huang F(2), Derraik JGB(3), Vickers MH(1), Devaraj S(4), Redeuil K(5), Campos-Giménez E(5), Pang WW(6), Godfrey KM(7), Chan SY(8), Thakkar SK(4), Cutfield WS(9); NiPPeR Study Group. Collaborators: Albert BB, Barton SJ, Binia A, Cavanagh M, Chang HF, Chong YS, Chong MF, Conlon C, Cooper C, Costello P, Cox V, Creagh C, Depczynski M, El-Heis S, Hammond J, Harvey NC, Jagtap M, Kenealy T, Nield H, O'Sullivan JM, Satianegara G, Silva-Zolezz I, Soh SE, Tay V, Taylor R, Tham E, Titcombe P, Wall C, Wong R, Woon G, Han Z. Author information: (1)Liggins Institute, The University of Auckland, Auckland, New Zealand. (2)Nestlé Research, Société des Produits Nestlé SA, Beijing, China. (3)Liggins Institute, The University of Auckland, Auckland, New Zealand; Department of Paediatrics: Child and Youth Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. (4)Nestlé Research, Société des Produits Nestlé SA, Singapore. (5)Nestlé Research, Société des Produits Nestlé SA, Lausanne, Switzerland. (6)Global Centre for Asian Women's Health, Dean's Office, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore. (7)MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK. (8)Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore; Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore. (9)Liggins Institute, The University of Auckland, Auckland, New Zealand; A Better Start - National Science Challenge, The University of Auckland, Auckland, New Zealand. Electronic address: w.cutfield@auckland.ac.nz. BACKGROUND & AIMS: Optimal maternal vitamin status during pregnancy and lactation is essential to support maternal and infant health. For instance, vitamin D3 is involved in infant bone development, and B-vitamins are involved in various metabolic processes, including energy production. Through a double-blind randomised controlled trial, we investigated the effects of maternal supplementation from preconception throughout pregnancy until birth on human milk (HM) concentrations of vitamin D3 and B-vitamins. In addition, we aimed to characterise longitudinal changes in milk concentrations of these vitamins. METHODS: Both control and intervention supplements contained calcium, iodine, iron, β-carotene, and folic acid, while the intervention also contained zinc, vitamins B2, B6, B12, and D3, probiotics, and myo-inositol. HM samples were collected across 4 time points from 1 week to 3 months post-delivery from 158 mothers in Singapore, and 7 time points from 1 week to 12 months from 180 mothers in New Zealand. HM vitamin D was quantified using supercritical fluid chromatography and B-vitamins with mass spectrometry. Potential intervention effects on HM vitamins D3, B2, B6, and B9, as well as other B-vitamin (B1 and B3) concentrations were assessed using linear mixed models with a repeated measures design. RESULTS: Over the first 3 months of lactation, HM 25-hydroxyvitamin D3 concentrations were 20% (95% CI 8%, 33%, P = 0.001) higher in the intervention group, with more marked effects in New Zealand. There were no observed intervention effects on HM concentrations of vitamins B1, B2, B3, B6, and B9. In New Zealand mothers, longitudinally, vitamin D3 concentrations gradually increased from early lactation up to 12 months, while vitamins B1 and B2 peaked at 6 weeks, B3 at 3 weeks, and B6 and B9 at 3 months. CONCLUSIONS: Maternal supplementation during preconception and pregnancy increased HM vitamin D, but not B-vitamin concentrations in lactation. Further studies are required to examine the discrete benefits of vitamin D supplementation starting preconception vs during pregnancy, and to further characterise the effects of supplementation on later offspring health outcomes. CLINICAL TRIAL REGISTRATION: Registered at ClinicalTrials.gov on the 16 July 2015 (identifier NCT02509988); Universal Trial Number U1111-1171-8056. This study was academic-led by the EpiGen Global Research Consortium. Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. DOI: 10.1016/j.clnu.2023.09.009 PMID: 38411017 [Indexed for MEDLINE]

From A to E: Uniting vitamins against stroke risk-A systematic review and network meta-analysis.

14. Eur J Clin Invest. 2024 Jun;54(6):e14165. doi: 10.1111/eci.14165. Epub 2024 Jan 30. From A to E: Uniting vitamins against stroke risk-A systematic review and network meta-analysis. Tripathi S(1), Nath M(1), Misra S(2), Kumar P(3). Author information: (1)Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. (2)Department of Neurology, Yale University, New Haven, Connecticut, USA. (3)Clinical Research Unit, All India Institute of Medical Sciences, New Delhi, India. BACKGROUND AND AIM: Stroke represents a significant public health challenge, necessitating the exploration of preventive measures. This network meta-analysis aimed to assess the efficacy of different vitamin treatments compared to a placebo in preventing stroke. METHODS: A systematic electronic search in databases including PubMed, EmBASE, Web of Science, clinicaltrials.gov, and Google Scholar until 31 May 2023 was conducted, to identify published studies investigating the association between vitamin intake and the risk of stroke. Pooled risk ratio (RR) with 95% confidence intervals (CIs) was calculated using a frequentist network meta-analysis. Furthermore, we ranked vitamins based on p-scores, facilitating a comparative assessment of their effectiveness in preventing stroke. RESULTS: A total of 56 studies, including 17 randomized controlled trials (RCTs) and 39 cohort studies were analyzed. Direct estimates obtained from network meta-analysis, we found that vitamin A (RR: .81 [.72-.91]), vitamin B-complex (RR: .85 [.74-.97]), vitamin B6 (RR: 79 [.68-.92]), folate (RR: .86 [.75-.97]), vitamin C (RR: .77 [.70-.85]) and vitamin D (RR: .73 [.64-.83]) were significantly associated with a decreased stroke risk. However, no significant association was observed for vitamin B2, vitamin B12, and vitamin E. Subsequent to network meta-analysis, vitamins were ranked in decreasing order of their efficacy in stroke prevention based on p-score, with vitamin D (p-score = .91), vitamin C (p-score = .79), vitamin B6 (p-score = .70), vitamin A (p-score = .65), vitamin B-complex (p-score = .53), folate (p-score = .49), vitamin B2 (p-score = .39), vitamin E (p-score = .28), vitamin B12 (.13) and placebo (.10). CONCLUSION: Our study has established noteworthy connections between vitamin A, vitamin B-complex, vitamin B6, folate, vitamin C, and vitamin D in the realm of stroke prevention. These findings add substantial weight to the accumulating evidence supporting the potential advantages of vitamin interventions in mitigating the risk of stroke. However, to solidify and validate these observations, additional research is imperative. Well-designed clinical trials or cohort studies are needed to further explore these associations and formulate clear guidelines for incorporating vitamin supplementation into effective stroke prevention strategies. © 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. DOI: 10.1111/eci.14165 PMID: 38291560 [Indexed for MEDLINE]

Effects of a low-protein nutritional formula with dietary counseling in older adults with chronic kidney disease stages 3-5: a randomized controlled trial.

15. BMC Nephrol. 2023 Dec 14;24(1):372. doi: 10.1186/s12882-023-03423-8. Effects of a low-protein nutritional formula with dietary counseling in older adults with chronic kidney disease stages 3-5: a randomized controlled trial. Yang WC(1), Hsieh HM(1), Chen JP(2), Liu LC(1), Chen CH(3)(4)(5)(6). Author information: (1)Department of Food and Nutrition, Taichung Veterans General Hospital, Taichung, Taiwan. (2)Biostatistics Group, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan. (3)Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Boulevard, Taichung, Taiwan. cschen920@yahoo.com. (4)Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University School of Medicine, Taichung, Taiwan. cschen920@yahoo.com. (5)Department of Life Science, Tunghai University, Taichung, Taiwan. cschen920@yahoo.com. (6)Program in Tissue Engineering and Regenerative Medicine, College of Medicine, National Chung-Hsing University, Taichung, Taiwan. cschen920@yahoo.com. BACKGROUND: Although combining a low-protein diet (LPD) with oral nutritional supplements increases treatment adherence and nutritional status in patients with chronic kidney disease (CKD), the effect of this combination approach in older adults remains unclear. This study examined the impact of a 6% low-protein formula (6% LPF) with diet counseling in older adults with stage 3-5 CKD. METHODS: In this three-month randomized controlled study, 66 patients (eGFR < 60 mL/min/1.73 m2, non-dialysis, over 65 years of age) were randomly assigned to an intervention group (LPD plus a 6% LPF) or control group (LPD alone). The 6% LPF comprised 400 kcal, 6 g of protein, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and various micronutrients. All data were collected at baseline and after three months, including physical performance based on hand grip strength (HGS) and gait speed, nutritional status using Mini Nutritional Assessment-Short Form (MNA-SF) scores, body composition through bioelectrical impedance analysis, and dietary intake from 24-h dietary records. RESULTS: This study incorporated 47 participants (median age, 73; median eGFR, 36 ml/min/1.73 m2; intervention group: 24; control group: 23). The intervention group exhibited significant differences in HGS and gait speed, and micronutrient analysis revealed significantly higher monounsaturated fatty acids (MUFA), EPA, DHA, calcium, iron, zinc, copper, thiamine, riboflavin, niacin, B6, B12, and folic acid intake than the control group. MNA-SF scores, macronutrient intake, and body composition did not differ significantly between the two groups. CONCLUSIONS: Compared to LPD counseling alone, an LPD prescription with 6% LPF in older adults with CKD stages 3-5 helped relieve physical deterioration and increased micronutrient intake after three months. TRIAL REGISTRATION: ClinicalTrials.gov NCT05318014 (retrospectively registered on 08/04/2022). © 2023. The Author(s). DOI: 10.1186/s12882-023-03423-8 PMCID: PMC10720150 PMID: 38097963 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no competing interests.